DLL1 and cutaneous melanoma: In addition, high PEBP1 expression was associated with a worse outcome of anti-PD-1 therapy in skin melanoma (Riaz, 2017 dataset) [46], but was related to better anti-D-L1 therapy outcomes in glioblastoma (Zhao, 2019 dataset) [47] (Figure 8F).